Last reviewed · How we verify
DelNS1-2019-nCoV-RBD-OPT1
At a glance
| Generic name | DelNS1-2019-nCoV-RBD-OPT1 |
|---|---|
| Sponsor | The University of Hong Kong |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults (PHASE4)
- To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DelNS1-2019-nCoV-RBD-OPT1 CI brief — competitive landscape report
- DelNS1-2019-nCoV-RBD-OPT1 updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI